Tcr2 Therapeutics — Technical Presentation (September 2021)
20 slides from Tcr2 Therapeutics's technical presentation, Sep 17, 2021
Slide 1: gavo-cel Phase 1/2 Clinical Update September 2021
gavo-cel Phase 1/2 Clinical Update September 2021 Exhibit 99.2
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation has been prepared by TCR2 Therapeutics Inc. (“we,” “us,” or “our”) and contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements are neither
Slide 3: Introduction
Introduction Garry Menzel, PhD Chief Executive Officer
Slide 4: Key Takeaways from gavo-cel Phase 1/2 Trial
Key Takeaways from gavo-cel Phase 1 Trial LD, Lymphodepletion; PR, Partial Response; ORR, Overall Response Rate; MTD, maximum tolerated dose; ODD, orphan drug designation; MPM, CCA Approaching RP2D Orphan Drug Designation for Mesothelioma and Cholangiocarcinoma Median OS (months) for MPM Patients 11
Slide 5: gavo-cel Clinical Trial Review
gavo-cel Clinical Trial Review Alfonso Quintás-Cardama, MD Chief Medical Officer
Slide 6: Ongoing gavo-cel Phase 1/2 Trial in MSLN+ Solid Tumors
Ongoing gavo-cel Phase 1 Trial in MSLN+ Solid Tumors LD, Lymphodepletion; RP2D, Recommended Phase 2 dose; MPM, Malignant Pleural/Peritoneal Mesothelioma; NSCLC, Non-Small Cell Lung Cancer; ODD, Orphan Drug Designation RP2D Phase 1: Dose Finding (‒ LD) Cohorts = 1 patient (+ LD) Cohorts = 3 patients
Slide 7: Patient Tumor Characteristics
Patient Tumor Characteristics Data Cutoff – June 30, 2021 Dose Level (gavo-cel dose) No. Patients DL 0 (no LD) 5x107/m2 n=1 DL 1 5x107/m2 n=6 DL 2 (no LD) 1x108/m2 n=1 DL 3 1x108/m2 n=5 DL 4 (no LD) 5x108/m2 n=1 DL 5 5x108/m2 n=3 Overall n=17 (%) Age, median (range) 61 69 (36-84) 46 46 (31-63) 67 52
Slide 8: Grade ≥3 Treatment Emergent Adverse Events
Grade ≥3 Treatment Emergent Adverse Events Data Cutoff – June 30, 2021 * Dose Limiting Toxicity Adverse Event DL 0 (no LD) 5x107/m2 n=1 (%) DL 1 5x107/m2 n=6 (%) DL 2 (no LD) 1x108/m2 n=1 (%) DL 3 1x108/m2 n=5 (%) DL 4 (no LD) 5x108/m2 n=1 (%) DL 5 5x108/m2 n=3 (%) Overall n=17 (%) Hematologic Lymph
Slide 9: Consistent Tumor Regression in Patients with gavo-cel
Consistent Tumor Regression in Patients with gavo-cel Change in Target Lesions from Baseline (%) MPM, malignant pleural/peritoneal mesothelioma; OVA, ovarian cancer; CHOLANGIO, cholangiocarcinoma; DL, dose level; LD, lymphodepletion; DCR, disease control rate; ORR, overall response rate All gavo-cel
Slide 10: Case Study: Patient 14 - Cholangiocarcinoma
Tumor Regression (56%*) 63-year-old female, Metastatic intrahepatic cholangiocarcinoma Mutated KRAS and RB1 Failed to respond to 5 prior lines of therapy Enrolled in gavo-cel Clinical Trial Study March 2021: Lymphodepletion with Flu/Cy followed by gavo-cel at 1x108/m2 Case Study: Patient 14 - Cholan
Slide 11: Case Study: Patient 15 - Mesothelioma
Partial Response (RECIST v1.1), Tumor Regression (55%) 66-year-old female, Relapsed pleural mesothelioma Failed 4 prior lines of therapy, including nivolumab/ipilimumab and anti-MSLN ADC Enrolled in gavo-cel Clinical Trial Study April 2021: Lymphodepletion with Flu/Cy followed by gavo-cel at 5x108/m
Slide 12: Case Study: Patient 5 – Ovarian Cancer
Partial Response (RECIST v1.1), Significant Tumor Regression (61%) 70-year-old female, High grade, Stage IV serous ovarian cancer TP53R248Q, CCNE1 amplified, wild type BRCA1/2 Failed 6 prior lines of therapy Platinum resistant Enrolled in gavo-cel Clinical Trial Study April 2020: Lymphodepletion wit
Slide 13: Patient Response and Follow-Up
LD No LD Patient Response and Follow-Up Overall Response Rate 25%, Disease Control Rate 81% Data Cutoff – June 30, 2021 Alive (ongoing) Survival post-PD DL1 DL2 DL3 DL4 DL3 DL5 DL0 DL3 DL3.5a
Slide 14: Survival of Patients with Mesothelioma
Data Cutoff – June 30, 2021 Survival of Patients with Mesothelioma Monotherapy n ORR (%) PFS (mo) OS (mo) Vinorelbine vs Supportive Care1 98 3.1 4.2 9.3 56 1.8 2.8 9.1 Pembrolizumab vs Vinorelbine or Gemcitabine2 73 22 2.5 10.7 71 6 3.4 12.4 Second Line MPM (Post Platinum-Based Frontline Therapy) ga
Slide 15: gavo-cel Peak Expansion and Plasma Cytokine Levels
gavo-cel Peak Expansion and Plasma Cytokine Levels Peak Expansion Peak IFN-�� Peak IL-6 5x107/m2 1x108/m2 5x108/m2 1x108/m2 5x108/m2 *
Slide 16: Clinical Trial Summary and Next Steps
Clinical Trial Summary and Next Steps Key Clinical Findings MTD identified (5x108/m2 with LD) Currently testing 3x108/m2 with LD to refine RP2D Clinical activity observed in all 3 solid tumor indications tested (DCR 81%, ORR 31% with LD) Meaningful ORR (38% with LD) and survival signal in mesothelio
Slide 17: Mesothelin Solid Tumors Represent a Significant Market
Mesothelin Solid Tumors Represent a Significant Market Percent of Patients with Mesothelin Surface Expression Refs: Inaguma 2017, SEER Statistics 2020, Morello 2016, Tozbikian 2014 Initial gavo-cel Indications Population: 80,000 patients Expansion Opportunities Population: 163,000 patients 76% Malig
Slide 18: The Path Forward – Powering a Solid Tumor Franchise
MSLN, CD70, GPC3 PD-1 Switch, IL-15, Dual TRuCs POC for Lead Candidate Solid Tumor Franchise Enhancements Allogeneic Platform Versatile TRuC Platform World Class Cell Therapy-Specific Leadership In-House Manufacturing Capabilities Cash as of 2Q21 ~$317M Expansion into Autoimmune Disease TRuC T-Regs
Slide 19: R&D Day – October 20, 2021
R&D Day – October 20, 2021 Further update on gavo-cel clinical trial and Phase 2 strategy Individual program reviews and pipeline strategy Allogeneic development candidate and strategy/timelines Development and data for TRuC T-reg T cells
Slide 20: Thank You
POWERING THE TCR TO TRANSFORM THE LIVES OF CANCER PATIENTS WITH SOLID TUMORS Thank You
TCR2 Therapeutics — Technical Presentation (September 2021) on 6ix